Cargando…

Plasmodium falciparum Plasmepsin 2 Duplications, West Africa

Dihydroartemisinin/piperaquine (DHA/PPQ) is increasingly deployed as an antimalaria drug in Africa. We report the detection in Mali of Plasmodium falciparum infections carrying plasmepsin 2 duplications (associated with piperaquine resistance) in 7/65 recurrent infections within 2 months after DHA/P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Juliana, Silva, Miguel, Fofana, Bakary, Sanogo, Kassim, Mårtensson, Andreas, Sagara, Issaka, Björkman, Anders, Veiga, Maria Isabel, Ferreira, Pedro Eduardo, Djimde, Abdoulaye, Gil, José Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2018
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056108/ https://www.ncbi.nlm.nih.gov/pubmed/29798744 http://dx.doi.org/10.3201/eid2408.180370

Ejemplares similares

Gametocyte clearance dynamics following oral artesunate treatment of uncomplicated falciparum malaria in Malian children
por: Djimde, Abdoulaye A., et al.
Publicado: (2016)

Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy
por: Kone, Aminatou, et al.
Publicado: (2020)

Plasmodium falciparum ookinete expression of plasmepsin VII and plasmepsin X
por: Li, Fengwu, et al.
Publicado: (2016)

Essentiality of Plasmodium falciparum plasmepsin V
por: Boonyalai, Nonlawat, et al.
Publicado: (2018)

Repeated Artemisinin-Based Combination Therapies in a Malaria Hyperendemic Area of Mali: Efficacy, Safety, and Public Health Impact
por: Sagara, Issaka, et al.
Publicado: (2012)

Differential Incidence of Malaria in Neighboring Villages in a High-Transmission Setting of Southern Mali
por: Fofana, Bakary, et al.
Publicado: (2022)

Differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria
por: Ouologuem, Dinkorma T., et al.
Publicado: (2018)

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali
por: Diarra, Modibo, et al.
Publicado: (2021)

Complexity of Plasmodium falciparum infection and genetic variations associated with differences in parasite clearance time in two Malian villages
por: Sissoko, Sekou, et al.
Publicado: (2023)

A randomized trial of dihydroartemisinin–piperaquine versus artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali
por: Dama, Souleymane, et al.
Publicado: (2018)

Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine
por: Loesbanluechai, Duangkamon, et al.
Publicado: (2018)

Trafficking of plasmepsin II to the food vacuole of the malaria parasite Plasmodium falciparum
por: Klemba, Michael, et al.
Publicado: (2004)

Assessment of Biological Role and Insight into Druggability of the Plasmodium falciparum Protease Plasmepsin V
por: Polino, Alexander J., et al.
Publicado: (2020)

In Silico and In Vitro Antimalarial Screening and Validation Targeting Plasmodium falciparum Plasmepsin V
por: Ji, Xin, et al.
Publicado: (2022)

Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali
por: Tekete, Mamadou, et al.
Publicado: (2009)

Plasmodium falciparum clearance with artemisinin-based combination therapy (ACT) in patients with glucose-6-phosphate dehydrogenase deficiency in Mali
por: Kone, Abdoulaye K, et al.
Publicado: (2010)

The nepenthesin insert in the Plasmodium falciparum aspartic protease plasmepsin V is necessary for enzyme function
por: Polino, Alexander J., et al.
Publicado: (2022)

Maturation and substrate processing topography of the Plasmodium falciparum invasion/egress protease plasmepsin X
por: Mukherjee, Sumit, et al.
Publicado: (2022)

Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali
por: Dama, Souleymane, et al.
Publicado: (2017)

Bioprospection of Selected Plant Secondary Metabolites as Modulators of the Proteolytic Activity of Plasmodium falciparum Plasmepsin V
por: Sulyman, Abdulhakeem Olarewaju, et al.
Publicado: (2023)

Relationship between weight status and anti-malarial drug efficacy and safety in children in Mali
por: Djimde, Moussa, et al.
Publicado: (2019)

Comparison of azithromycin plus chloroquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children in Africa: a randomized, open-label study
por: Chandra, Richa, et al.
Publicado: (2015)

Understanding the structural basis of substrate recognition by Plasmodium falciparum plasmepsin V to aid in the design of potent inhibitors
por: Bedi, Rajiv K., et al.
Publicado: (2016)

Plasmepsin II–III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum
por: Bopp, Selina, et al.
Publicado: (2018)

Plasmepsin X activates the PCRCR complex of Plasmodium falciparum by processing PfRh5 for erythrocyte invasion
por: Triglia, Tony, et al.
Publicado: (2023)

Plasmodium falciparum with Multidrug Resistance 1 Gene Duplications, Senegal
por: Pascual, Aurélie, et al.
Publicado: (2013)

A Plasmodium falciparum genetic cross reveals the contributions of pfcrt and plasmepsin II/III to piperaquine drug resistance
por: Kane, John, et al.
Publicado: (2023)

Computational Perspectives into Plasmepsins Structure—Function Relationship: Implications to Inhibitors Design
por: Gil L., Alejandro, et al.
Publicado: (2011)

Antimalarial Exposure Delays Plasmodium falciparum Intra-Erythrocytic Cycle and Drives Drug Transporter Genes Expression
por: Veiga, Maria Isabel, et al.
Publicado: (2010)

Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte
por: Russo, Ilaria, et al.
Publicado: (2010)

Experimental Determination of the Membrane Topology of the Plasmodium Protease Plasmepsin V
por: Tarr, Sarah J., et al.
Publicado: (2015)

Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso
por: Beshir, Khalid B., et al.
Publicado: (2021)

Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria
por: Carlsson, Anja M, et al.
Publicado: (2011)

Plasmodium falciparum Drug Resistance Genes pfmdr1 and pfcrt In Vivo Co-Expression During Artemether-Lumefantrine Therapy
por: Silva, M., et al.
Publicado: (2022)

Disulfide Linkages in Plasmodium falciparum Plasmepsin-I Are Essential Elements for Its Processing Activity and Multi-Milligram Recombinant Production Yield
por: Lolupiman, Sirisak, et al.
Publicado: (2014)

Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar
por: Pernaute-Lau, Leyre, et al.
Publicado: (2021)

Imperfect Duplicate Insertions Type of Mutations in Plasmepsin V Modulates Binding Properties of PEXEL Motifs of Export Proteins in Indian Plasmodium vivax
por: Rawat, Manmeet, et al.
Publicado: (2013)

Plasmodium falciparum Development from Gametocyte to Oocyst: Insight from Functional Studies
por: Ouologuem, Dinkorma T., et al.
Publicado: (2023)

Plasmodium falciparum Drug Resistance Phenotype as Assessed by Patient Antimalarial Drug Levels and Its Association With pfmdr1 Polymorphisms
por: Malmberg, Maja, et al.
Publicado: (2013)

Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial Activity
por: Richardson, Lachlan W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s8j9ssf13b6ke1fvmr4bv2evl3